ARTV
Artiva Biotherapeutics Inc

801
Mkt Cap
$97.93M
Volume
20,337.00
52W High
$7.36
52W Low
$1.47
PE Ratio
-1.23
ARTV Fundamentals
Price
$4.08
Prev Close
$3.99
Open
$4.00
50D MA
$4.23
Beta
1.39
Avg. Volume
222,646.35
EPS (Annual)
-$2.69
P/B
0.76
Rev/Employee
$2,820.22
$73.79
Loading...
Loading...
News
all
press releases
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Rating of "Moderate Buy" from Brokerages
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) has been given a consensus rating of "Moderate Buy" by the six analysts that are presently covering the stock, Marketbeat.com reports. One...
MarketBeat·8d ago
News Placeholder
More News
News Placeholder
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Sees Significant Decline in Short Interest
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) saw a large drop in short interest in January. As of January 15th, there was short interest totaling 284,944 shares, a drop of 27.1% from...
MarketBeat·12d ago
News Placeholder
Brokers Set Expectations for ARTV FY2030 Earnings
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of Artiva Biotherapeutics in a research report issued...
MarketBeat·17d ago
News Placeholder
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Recommendation of "Moderate Buy" from Brokerages
Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six ratings firms that are presently covering the company...
MarketBeat·2mo ago
News Placeholder
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) has been given an average rating of "Moderate Buy" by the six ratings firms that are presently covering the stock, MarketBeat Ratings...
MarketBeat·3mo ago
News Placeholder
Artiva Biotherapeutics (NASDAQ:ARTV) CEO Sells $21,547.50 in Stock
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) CEO Fred Aslan sold 6,375 shares of the business's stock in a transaction on Monday, November 17th. The shares were sold at an average...
MarketBeat·3mo ago
News Placeholder
Fred Aslan Sells 6,375 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) CEO Fred Aslan sold 6,375 shares of the stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average...
MarketBeat·3mo ago
News Placeholder
HC Wainwright Forecasts Strong Price Appreciation for Artiva Biotherapeutics (NASDAQ:ARTV) Stock
HC Wainwright boosted their target price on shares of Artiva Biotherapeutics from $12.00 to $15.00 and gave the company a "buy" rating in a research note on Wednesday...
MarketBeat·3mo ago
News Placeholder
Artiva Biotherapeutics (NASDAQ:ARTV) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS
Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus...
MarketBeat·3mo ago
News Placeholder
Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally
Wedbush’s new price target implies a whopping 730% potential upside to the stock’s closing price on Thursday.
Stocktwits·4mo ago
<
1
2
...
>

Latest ARTV News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.